Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month High – What’s Next?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $14.56 and last traded at $14.27, with a volume of 969751 shares. The stock had previously closed at $13.99.

Key Headlines Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Bullish independent thesis — A Seeking Alpha write‑up upgrades Cullinan to a Buy, highlighting a deep T‑cell engager pipeline (notably CLN‑049 showing ~30% CR in AML), a strong cash runway (~$430M+), and a clear regulatory path that supports upside expectations. Seeking Alpha: Thesis Strengthening For This T-Cell Engager Specialist
• Positive Sentiment: Investor conference participation — Management (CEO Nadim Ahmed and CMO Jeffrey Jones) announced attendance at upcoming investor conferences, which increases investor access to clinical updates and can support multiple‑stakeholder visibility. GlobeNewswire: Cullinan Therapeutics to Participate in Upcoming Investor Conferences
• Positive Sentiment: Analyst momentum — Multiple firms have issued Buy/Outperform ratings and lifted price targets in recent months (consensus/average target materially above current levels), which can attract momentum buyers. MarketBeat: CGEM analyst coverage
• Neutral Sentiment: Technical/fundamental backdrop — The stock is trading above the 50‑ and 200‑day moving averages and is well above its 52‑week low, reflecting short‑term strength; market cap and high institutional ownership (~86%) mean moves can be amplified by flows. MarketBeat: CGEM profile
• Negative Sentiment: Clustered insider sales — Several insiders (CEO Nadim Ahmed, CFO Mary Kay Fenton and others) sold shares around Feb 20 (combined ~20k+ shares across multiple filings). While the percentages trimmed are modest (low single digits), simultaneous sales by senior executives can create near‑term selling pressure and raise questions for some traders. InsiderTrades: CGEM insider transactions

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CGEM. BTIG Research upped their price objective on shares of Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, November 24th. Wedbush boosted their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Morgan Stanley reissued an “overweight” rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a report on Thursday, January 8th. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Finally, New Street Research set a $26.00 target price on Cullinan Therapeutics in a report on Thursday, November 20th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Cullinan Therapeutics Price Performance

The company has a market capitalization of $843.01 million, a P/E ratio of -4.31 and a beta of -0.09. The stock’s fifty day simple moving average is $11.41 and its 200-day simple moving average is $9.27.

Insider Transactions at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $14.08, for a total value of $165,327.36. Following the transaction, the insider directly owned 181,977 shares of the company’s stock, valued at $2,562,236.16. The trade was a 6.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jacquelyn L. Sumer sold 3,742 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $13.62, for a total value of $50,966.04. Following the transaction, the insider owned 131,690 shares of the company’s stock, valued at approximately $1,793,617.80. This trade represents a 2.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 71,081 shares of company stock worth $879,045. Insiders own 6.07% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Several large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in Cullinan Therapeutics by 62.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock valued at $28,000 after purchasing an additional 1,036 shares during the period. CWM LLC lifted its stake in shares of Cullinan Therapeutics by 51.5% in the fourth quarter. CWM LLC now owns 3,876 shares of the company’s stock valued at $40,000 after buying an additional 1,318 shares during the period. Signaturefd LLC grew its position in Cullinan Therapeutics by 689.7% during the fourth quarter. Signaturefd LLC now owns 4,130 shares of the company’s stock worth $43,000 after buying an additional 3,607 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Cullinan Therapeutics during the third quarter worth about $62,000. Finally, Tower Research Capital LLC TRC increased its stake in Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after acquiring an additional 2,523 shares during the period. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.